DRRX
$1.89
Durect
($.05)
(2.58%)
DRRX
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  ($0.01)
Revenue:  $10.38 Mil
Monday
Feb 3
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when DRRX reports earnings?
Beat
Meet
Miss

Where is DRRX's stock price going from here?
Up
Flat
Down
Stock chart of DRRX
Analysts
Summary of analysts' recommendations for DRRX
Score
Grade
Pivots
Resistance
$2.09
$2.04
$1.97

$1.91

Support
$1.84
$1.78
$1.71
Tweet
Growth
Description
Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from the medical device and drug delivery industries with its proprietary pharmaceutical and biotechnology drug formulations.
Peers
BioMarin PharmaceuticalRegeneron PharmaceuticalsVertex PharmaceuticalsCelgeneInterCeptJohnson & JohnsonZoetisEndo International plcMylanUltragenyx Pharmaceutical